Gerald (Gerry) Cox, MD, PhD is the founder of Gerald Cox Rare Care Consulting, where he advises biotech companies and provides clinical development solutions for investigational rare disease treatments. Prior to that, he led clinical development programs of CRISPR-editing therapies for genetic diseases as Chief Medical Officer for Editas Medicine. Earlier in his career, Dr. Cox served as Vice President of Rare Disease Clinical Development at Sanofi Genzyme, where he oversaw clinical development programs for several rare disease treatments, including for Aldurazyme®, Myozyme®, Elaprase®, Cerdelga®, Xenpozyme®, Hectoral®, Cerezyme®, and venglustat. Dr. Cox is a part-time practicing geneticist at Boston Children's Hospital and an instructor in Pediatrics at Harvard Medical School. He is board-certified in Clinical, Biochemical, and Molecular Genetics. Dr. Cox is on the board of directors for the National Tay-Sachs and Allied Diseases patient advocacy organization, and he is a member of the scientific and medical advisory committees for the National Organization for Rare Diseases and the CTNNB1 patient advocacy organization. He is a member of the Data Monitoring Committee for two gene therapy companies. Dr. Cox’s clinical interests include novel approaches to treating genetic diseases, genetic eye diseases, lysosomal storage disorders, pediatric cardiomyopathy, neuromuscular disorders, and Barth Syndrome.
